All Products
Contact Person :
Bruce Lee
Phone Number :
+8618874586545
WhatsApp :
+8618874586545
High Purity 99% BMS-262084 China Supplier CAS 253174-92-4 For Treating Asthma
| Place of Origin | China |
|---|---|
| Brand Name | XRD |
| Certification | GMP |
| Model Number | 253174-92-4 |
| Minimum Order Quantity | negotiable |
| Price | Inquiry for Negotiable |
| Packaging Details | 1-2 kg / aluminum foil bag, 25kg/ drum, as required |
| Delivery Time | 1-2days after payment received |
| Payment Terms | T/T bank, Western Union, Bitcoin, Etc |
| Supply Ability | 1000KG/ Month |
Contact me for free samples and coupons.
Whatsapp:0086 18588475571
Wechat: 0086 18588475571
Skype: sales10@aixton.com
If you have any concern, we provide 24-hour online help.
xProduct Details
| CAS | 253174-92-4 | Product Name | BMS-262084 |
|---|---|---|---|
| Type | Intermediates | Appearance | Yellow Powder |
| Usage | For Treating Asthma | Alias | BMS-262084 |
| Assay | 99% | Key Words | BMS-262084 |
| High Light | Yellow Benzodiazepine Powder,99% Benzodiazepine Powder,Pharmaceutical Intermediate CAS 137350-66-4 |
||
Product Description
99% BMS-262084 Manufacturer CAS 253174-92-4 For Treating Asthma
Quick Detail
Produce name : BMS-262084
CAS number : 253174-92-4
| Synonyms: | BMS-262084; BMS 262084; BMS262084; CHEMBL71037; UNII-I0IR71971G; I0IR71971G; BDBM50120368; DNC004491.;2-Azetidinecarboxylic acid, 3-(3-((aminoiminomethyl)amino)propyl)-1-((4-(((1,1-dimethylethyl)amino)carbonyl)-1-piperazinyl)carbonyl)-4-oxo-, (2S,3R) |
BMS‐262084 is a potent and selective β‐lactam tryptase inhibitor with therapeutic potential for treating asthma. The oral bioavailability of BMS‐262084 was low in rats (4% at a dose of 0.5 mg/kg) due to poor absorption. BMS‐262084 was excreted mainly unchanged in the urine, suggesting minimal metabolism in rats. The objective of this study was to investigate the mechanisms of oral absorption of BMS‐262084 in rats. Modulation of intestinal tight junctions, binding to trypsin, and involvement of the intestinal dipeptide transport system and P‐glycoprotein (P‐gp) in the absorption of BMS‐262084 were examined. Coadministration of BMS‐262084 with SQ‐29852, a substrate of the intestinal dipeptide transport system, did not change the oral absorption of BMS‐262084. An increase in the dose of BMS‐262084 from 0.5 to 50 mg/kg resulted in a 3.7‐fold increase in its oral absorption. Inulin absorption was enhanced upon coadministration with BMS‐262084, suggesting the opening of tight junctions in the intestinal epithelium. Coadministration of aprotinin, a trypsin inhibitor, increased the oral absorption of BMS‐262084 several fold. In vitro, using Caco‐2 cells, BMS‐262084 appeared to be a P‐gp substrate, with an efflux ratio of 14. These results suggest that absorption of BMS‐262084 is mediated by several concurrent mechanisms. At higher doses of BMS‐262084, increased absorption may be primarily due to opening of tight junctions in the intestinal epithelium and consequent absorption via the paracellular pathway, while at lower doses, binding to trypsin may contribute to limiting its absorption. P‐gp efflux may also play a role in influencing the absorption of BMS‐262084. The intestinal dipeptide transporter system does not appear to be involved in the absorption of BMS‐262084.
99% BMS-262084 Manufacturer CAS 253174-92-4 For Treating Asthma
Recommended Products